(NYSEMKT: STXS) Stereotaxis's forecast annual revenue growth rate of 39.84% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 14.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.26%.
Stereotaxis's revenue in 2026 is $31,195,000.On average, 7 Wall Street analysts forecast STXS's revenue for 2026 to be $4,057,441,364, with the lowest STXS revenue forecast at $3,831,278,640, and the highest STXS revenue forecast at $4,310,188,470. On average, 7 Wall Street analysts forecast STXS's revenue for 2027 to be $5,293,615,145, with the lowest STXS revenue forecast at $4,597,534,368, and the highest STXS revenue forecast at $6,095,837,979.
In 2027, STXS is forecast to generate $5,293,615,145 in revenue, with the lowest revenue forecast at $4,597,534,368 and the highest revenue forecast at $6,095,837,979.